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Adiponectin, a 30 kDa protein produced mainly by mature adipocytes, has been implicated in a wide spectrum of 
biological pathways related to peripheral insulin sensitivity,1 in-
flammatory response,1,2 and atherogenesis.2 In contrast to most 
adipokines, adiponectin secretion is downregulated in obese in-
dividuals.3 Observational epidemiological studies support that 
hypoadiponectinemia is associated with cardiovascular risk fac-
tors4,5 (eg, insulin resistance and dyslipidemia) and type 2 dia-
betes mellitus risk6; inconsistent findings have been observed 
on coronary heart disease (CHD)7–10 and stroke risk.9,11
Editorial, see p 407 
In This Issue, see p 397
Mendelian randomization studies make use of genetic 
variants as instrumental variables to investigate the effect 
of environmental exposures and biomarkers on outcomes. 
Because alleles are randomly allocated during gametogenesis 
and genotype is a fixed exposure, Mendelian randomization 
studies are not as vulnerable to confounding and reverse cau-
sality and can substantially improve causal inference from 
observational data.12 Mendelian randomization is regarded 
as nature’s analogue of randomized controlled trials and has 
successfully been used in cardiovascular research to investi-
gate potential etiologic mechanisms,13 validate and prioritize 
novel drug targets,14 and increase understanding of current 
therapies.15
Clinical Track
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Rationale: Hypoadiponectinemia correlates with several coronary heart disease (CHD) risk factors. However, it is 
unknown whether adiponectin is causally implicated in CHD pathogenesis.
Objective: We aimed to investigate the causal effect of adiponectin on CHD risk.
Methods and Results: We undertook a Mendelian randomization study using data from genome-wide association 
studies consortia. We used the ADIPOGen consortium to identify genetic variants that could be used as 
instrumental variables for the effect of adiponectin. Data on the association of these genetic variants with CHD 
risk were obtained from CARDIoGRAM (22 233 CHD cases and 64 762 controls of European ancestry) and from 
CARDIoGRAMplusC4D Metabochip (63 746 cases and 130 681 controls; ≈ 91% of European ancestry) consortia. 
Data on the association of genetic variants with adiponectin levels and with CHD were combined to estimate the 
influence of blood adiponectin on CHD risk. In the conservative approach (restricted to using variants within 
the adiponectin gene as instrumental variables), each 1 U increase in log blood adiponectin concentration was 
associated with an odds ratio for CHD of 0.83 (95% confidence interval, 0.68–1.01) in CARDIoGRAM and 0.97 
(95% confidence interval, 0.84–1.12) in CARDIoGRAMplusC4D Metabochip. Findings from the liberal approach 
(including variants in any locus across the genome) indicated a protective effect of adiponectin that was attenuated 
to the null after adjustment for known CHD predictors.
Conclusions: Overall, our findings do not support a causal role of adiponectin levels in CHD pathogenesis. 
(Circ Res. 2016;119:491-499. DOI: 10.1161/CIRCRESAHA.116.308716.)
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There is evidence of a shared allelic architecture of circu-
lating adiponectin with CHD risk and carotid intima–media 
thickness16,17; however, it remains unanswered if these findings 
implicate a causal effect of adiponectin on CHD risk or merely 
shared pleiotropic factors. Our aim was to investigate the causal ef-
fect of adiponectin on CHD risk using Mendelian randomization.
Methods
Study Design
We performed a 2-sample Mendelian randomization analysis using 
summary data from genome-wide association studies (GWAS) consor-
tia. Single-nucleotide polymorphisms (SNPs), previously reported to 
be associated with blood adiponectin levels, were used as instrumental 
variables for testing the causal effect of adiponectin on CHD risk. Data 
on the association of SNPs with (1) adiponectin levels (first sample) and 
(2) CHD risk (second samples) were combined to estimate the influence 
of blood adiponectin on CHD risk. To investigate the presence of poten-
tial bias (horizontal pleiotropy) or mediation of the effect of adiponectin 
on CHD via other CHD risk factors (vertical pleiotropy; Online Figure 
I), we also analyzed data on the association of the selected adiponectin-
related SNPs with a range of CHD risk factors: glycohemoglobin, fast-
ing insulin, high-density lipoprotein cholesterol (HDL-c), low-density 
lipoprotein cholesterol (LDL-c), triacylglycerols (TAG), body mass in-
dex (BMI), and BMI-adjusted waist circumference (WC).
Data Sources
Summary data on the association between SNPs and the pheno-
types of interest were extracted from public databases of different 
consortia: ADIPOGen for adiponectin18; CARDIoGRAM (Coronary 
ARtery DIsease Genome-wide Replication And Meta-analysis)19 and 
CARDIoGRAMplusC4D Metabochip (CARDIoGRAMplusC4D 
Metabochip and GWAS meta-analysis)20 for CHD; MAGIC (Meta-
Analyses of Glucose and Insulin-Related Traits Consortium) for 
glycohemoglobin21 and fasting insulin22; GLGC (Global Lipids 
Genetics Consortium) for HDL-c, LDL-c, and TAG23; and GIANT 
(Genetic Investigation of ANthropometric Traits) for BMI24 and 
WC.25 Details about each data source are displayed in Online 
Table I. CARDIoGRAMplusC4D Metabochip includes data from 
CARDIoGRAM GWAS.
Instrumental Variables
The SNPs for our main instrumental variable analyses (n=17 SNPs) 
were selected from 145 SNPs strongly (P<5×10−8) associated with 
blood adiponectin levels in the European ancestry GWAS meta-anal-
ysis from the ADIPOGen consortium.18 Independent SNPs were pre-
viously selected by Dastani et al16 by linkage disequilibrium pruning 
of the genome-wide significant SNPs, retaining SNPs that explained 
most variance in adiponectin levels in each linkage disequilibrium 
block (linkage disequilibrium threshold: R2<0.05 in HapMap CEU 
population [Utah residents with Northern and Western European an-
cestry]; Table 1).
We used 2 sets of instruments (Figure 1):
1. A conservative instrumental variable analysis, in which only 
SNPs within the ADIPOQ locus (±50 kb) were considered eli-
gible (n=4 SNPs; C4). ADIPOQ is mainly expressed in adipose 
tissue and encodes adiponectin. We considered this approach 
unlikely to be biased by horizontal pleiotropy given the func-
tional relationship of ADIPOQ to adiponectin levels.
2. A liberal analysis, in which independent SNPs from any lo-
cus that had reached a genome-wide significant association 
(P<5*10−8) with adiponectin levels in the ADIPOGen consor-
tia GWAS (n=17 SNPs), were included (L17), as previously 
reported by Dastani et al.16 These 17 SNPs included the four 
SNPs within the ADIPOQ locus.
Ten of the 17 selected SNPs could be found in 
CARDIoGRAMplusC4D Metabochip data, 3 of which were proxy 
SNPs (R2>0.95 for CEU population). For the remaining 7 SNPs, 
data from CARDIoGRAM GWAS was used. As the SNP rs1108842 
could not be found in GLGC data, a proxy SNP (rs13083798) in per-
fect linkage disequilibrium (R2=1.0 for CEU population) was used 
instead.
Validation of Instrumental Variable Assumptions
Validity of Mendelian randomization analyses results can be compro-
mised if the instrumental variable assumptions are violated. In Online 
Table II, we described the 3 core assumptions of instrumental variable 
analysis and the strategies used to address these.
Estimation of Causal Effect
For both liberal and conservative approaches, the β coefficient (log 
odds ratio of CHD per one natural log greater adiponectin level) 
and its SE were calculated using the inverse-variance weighted 
(IVW) method as described by Burgess et al.26 (See Online Data 
Supplement).
For the liberal approach, we also used the IVW method to es-
timate the combined effect of adiponectin levels on cardiovascular 
risk factors (glycohemoglobin, fasting insulin levels, HDL-c, LDL-c, 
TAG, BMI, and WC). Where we found evidence of an effect of the 
SNPs on these risk factors, estimates of the association between 
adiponectin and CHD were adjusted for these risk factors to reduce 
the possibility that horizontal pleiotropy biased our findings27 (See 
Online Data Supplement).
Sensitivity Analyses
Assuming that all valid instrumental variables identify the same 
causal parameter, substantial heterogeneity would be suggestive of 
pleiotropic SNPs. We evaluated heterogeneity in our IVW estimates 
using standard tools from the meta-analysis literature: forest plot of 
per SNP ratio estimate, Cochran Q test, and I2 values.28–30 In addition, 
to identify overly influential SNPs, additional meta-analyses were 
performed by removing 1 SNP at a time and recalculating the overall 
instrumental variable estimates.
Nonstandard Abbreviations and Acronyms
BMI body mass index
C4  conservative instrumental variable analysis 
approach
CARDIoGRAM  Coronary ARtery DIsease Genome-wide 
Replication And Meta- analysis
CARDIoGRAMplusC4D   CARDIoGRAMplusC4D Metabochip and GWAS 
Metabochip  meta-analysis
CEU  Utah residents with Northern and Western 
European ancestry
CHD coronary heart disease
CI confidence interval
GIANT Genetic Investigation of ANthropometric Traits
GLGC Global Lipids Genetics Consortium
GWAS genome-wide association studies
HDL-c high-density lipoprotein cholesterol
IVW inverse-variance weighted
L17 liberal instrumental variable analysis approach
LDL-c low-density lipoprotein cholesterol
MAGIC  Meta-Analyses of Glucose and Insulin-Related 
Traits Consortium
OR odds ratio
SNP single-nucleotide polymorphisms
TAG triacylglycerols
WC waist circumference
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Even after adjusting for cardiovascular risk factors associated 
with our instrument, the liberal approach estimates could still be 
biased by unknown horizontal pleiotropic pathways that link the 
adiponectin genetic instrumental variable to CHD independently of 
path through adiponectin. To explore the presence of this possible 
bias, the MR-Egger regression method was used.31 See Online Data 
Supplement for a description of this method.
We also undertook a positive control analysis that consisted of 
a Mendelian randomization analysis in which LDL-c was the bio-
marker of interest and CHD risk was the outcome (using the IVW 
and MR-Egger method) because of its established causal role in CHD 
development (see Online Data Supplement).
Results
Association of the Genetic Instrument With 
Adiponectin and CHD Risk
Figure 2 shows the associations of SNPs, used as instrumen-
tal variables in the conservative (n=4 SNPs within ADIPOQ 
gene) and liberal analyses (n=17 SNPs across the genome), 
with adiponectin levels and CHD risk. For the conservative ap-
proach, each adiponectin-increasing allele was associated with 
2.3% reduction in CHD risk (95% confidence interval [CI], 
−4.1 to −0.4) in CARDIoGRAM data and 0.6% reduction in 
CHD risk (95% CI, −1.9 to 1.0) in CARDIoGRAMplusC4D 
Metabochip. For the liberal approach, each adiponectin-in-
creasing allele was associated with 2.3% reduction in CHD 
risk (95% CI, −3.2 to −1.5) in CARDIoGRAM data and 
1.7% reduction in CHD risk (95% CI, −2.3 to −1.1%) in 
CARDIoGRAMplusC4D Metabochip. Of the 17 SNPs, there 
was some evidence of heterogeneity (P<0.05) between studies 
that contributed to each consortium for 3 SNPs: 2 SNPs in 
CARDIoGRAM (rs1108842 and rs6488898) and 1 SNP in 
CARDIoGRAMplusC4D Metabochip (rs3774261).
Association of the Genetic Instruments With CHD 
Risk Factors
More than 50% of individual SNPs were associated with one 
or more CHD risk factor (glycohemoglobin, fasting insulin 
levels, HDL-c, LDL-c, TAG, BMI, and WC), and none of these 
SNPs were located within ADIPOQ gene (±50 kb; Table 2). In 
general, adiponectin-increasing variants were not associated 
with CHD risk factors in the conservative approach but were 
related to lower fasting insulin, higher HDL-c, lower TAG, 
lower WC, and higher BMI in the liberal approach (Figure 3).
Effect of Blood Adiponectin Concentration  
on CHD Risk
Figure 4 shows the results of all Mendelian randomization 
analyses assessing the association of genetically predicted 
adiponectin with CHD risk. Using the conservative ap-
proach (including only the 4 SNPs within ADIPOQ gene), 
each unit increase in log adiponectin concentration was as-
sociated with an odds ratio for CHD of 0.83 (95% CI, 0.68–
1.01) in CARDIoGRAM and 0.97 (95% CI, 0.84–1.12) in 
CARDIoGRAMplusC4D Metabochip data set. Using the lib-
eral approach (including 17 SNPs), the odds ratio (OR) for the 
effect of each unit increase in log adiponectin concentration 
on CHD was 0.76 (95% CI, 0.65–0.89) in CARDIoGRAM 
and 0.83 (95% CI, 0.74–0.93) in CARDIoGRAMplusC4D 
Table 1. Characteristics of SNPs Selected for Each Analytic Approach
SNP Chr Position* Closest Gene EA NEA EAF† C4 L17
rs1415293 1 219730006 ZC3H11B T A 0.25 … √
rs1108842 3 52720080 GNL3 C A 0.49 … √
rs6810075 3 186548565 ADIPOQ T C 0.61 √ √
rs16861209 3 186563114 ADIPOQ A C 0.08 √ √
rs17366568 3 186570453 ADIPOQ-AS1, ADIPOQ G A 0.93 √ √
rs3774261 3 186571559 ADIPOQ-AS1, ADIPOQ A G 0.50 √ √
rs998584 6 43757896 VEGFA C A 0.54 … √
rs2980880 8 126480972 TRIB1 A G 0.71 … √
rs7955516 12 20498036 PDE3A C A 0.28 … √
rs601339 12 123174743 HCAR2 G A 0.25 … √
rs6488898 12 124203832 ATP6V0A2 A G 0.98 … √
rs7978610 12 124468572 ZNF664, FAM101A C G 0.27 … √
rs2925979 16 81534790 CMIP C T 0.71 … √
rs7200895 16 82644606 CDH13 T C 0.69 … √
rs8047711 16 82667671 CDH13 G A 0.92 … √
rs12929479 16 82997853 CDH13 G A 0.42 … √
rs731839 19 33899065 PEPD A G 0.54 … √
C4 indicates the 4 SNPs used in the conservative analyses; Chr indicates chromosome; EA, effect allele; EAF, effect 
allele frequency; L17, 17 SNPs used in the liberal analyses (SNPs selected on the basis of reaching genome-wide 
significant levels in association with adiponectin, P<5×10−8); and NEA, noneffect allele.
*Genome Reference Consortium Human Build 37.
†1000 Genomes.
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Metabochip. When we adjusted these liberal approach results 
for the CHD risk factors associated with the genetic instru-
ment (fasting insulin, HDL-c, TAG, WC, and BMI), the OR 
was 0.88 (95% CI, 0.75–1.03) in CARDIoGRAM and 1.00 
(95% CI, 0.90–1.12) in CARDIoGRAMplusC4D Metabochip.
Sensitivity Analyses
There was substantial heterogeneity in IVW estimates among 
the 17 SNPs from the liberal approach in both CARDIoGRAM 
(I2=65.2; P=1×10−4) and CARDIoGRAMplusC4D Metabochip 
(I2=72.4; P=2×10−6) data (Online Figure II). The effect of re-
moving one SNP at a time on the overall estimate showed 
that no SNP could explain the observed protective effect in 
the liberal analysis. The inclusion of the SNPs rs17366568 
and rs8047711 slightly underestimated findings from the IVW 
method in CARDIoGRAM data set (Online Figure III).
By using the MR-Egger method with our liberal instru-
ment, we observed further evidence of directional pleiotropy, 
that is, the instrument was associated with a decreased log 
odds of CHD independently of its effect on adiponectin in 
CARDIoGRAM (log OR, −0.03; 95% CI: −0.05 to −0.02 for 
the intercept) and in CARDIoGRAMplusC4D Metabochip 
(log OR, −0.03; 95% CI, −0.05 to −0.02 for the intercept; 
Online Figure IV). According to Mendelian randomization 
estimates using the MR-Egger method, each unit increase 
in log adiponectin concentration was associated with an OR 
for CHD of 1.25 (95% CI, 0.96–1.63) in CARDIoGRAM 
and 1.30 (95% CI, 1.06–1.58) in CARDIoGRAMplusC4D 
Metabochip data set (Figure 4). In the influence meta-analy-
sis, in which we removed 1 of the 17 SNPs at a time from the 
pooled estimates, all of the results for the remaining 16 SNPs 
were in the same (positive) direction, but the magnitude of this 
varied somewhat (Online Figure III).
To investigate any differences between CARDIoGRAM 
and CARDIoGRAMplusC4D Metabochip, we compared 
Mendelian randomization results of the effect of LDL-c on 
CHD risk (positive control analysis). The OR for CHD for 
each standardized unit increase in LDL-c was 1.70 (95% CI, 
1.54–1.88) in CARDIoGRAM and 1.57 (95% CI, 1.47–1.67) 
in CARDIoGRAMplusC4D Metabochip. After accounting 
for unknown horizontal pleiotropy (MR-Egger method), es-
timates were 1.96 (95% CI, 1.59–2.33) for CARDIoGRAM 
and 1.92 (95% CI, 1.65–2.17) for CARDIoGRAMplusC4D 
Metabochip.
Discussion
Taken together, our results are not supportive of a protective 
causal effect of adiponectin on CHD risk. First, we found no 
consistent evidence that genetic predisposition to elevated 
blood adiponectin levels is associated to reduced risk of CHD 
in the analysis restricted to ADIPOQ SNPs (conservative ap-
proach). Second, in the more liberal analysis, using variants 
associated with adiponectin across the genome, there was evi-
dence of a protective effect, but this was because of horizontal 
pleiotropy. This conclusion regarding horizontal pleiotropy 
resulting in a biased apparent protective effect with our lib-
eral approach is supported by both multivariable Mendelian 
randomization and MR-Egger. Some of the variants strongly 
associated with circulating adiponectin, in our liberal analysis, 
Figure 1. Analysis plan. Summary data from the association of single-nucleotide polymorphism (SNP) with phenotypes were extracted 
from genome-wide association study (GWAS) consortia data sets (ADIPOGen, CARDIoGRAM, C4D, MAGIC, GLGC, and GIANT). The 
effect of adiponectin on CHD was estimated using a conservative Mendelian randomization approach (instrumental variable: SNPs 
within ADIPOQ locus [±50 kb]) and a liberal approach (instrumental variable: SNPs in any locus). For the conservative approach, inverse-
variance weighted (IVW) method was used. For the liberal approach, IVW method was used in both crude and adjusted analysis for 
known pleiotropic factors and MR-Egger regression in the analysis accounting for hidden pleiotropy (sensitivity analysis). BMI indicates 
body mass index; CARDIoGRAM, Coronary Artery Disease Genome-wide Replication and Meta-analysis; CARDIoGRAMplusC4D 
Metabochip, CARDIoGRAMplusC4D Metabochip meta-analysis; GIANT, genetic investigation of anthropometric traits; GLGC, Global 
Lipids Genetics Consortium; HbA1c: glycohemoglobin; HDL, high-density lipoprotein; IV, instrumental variable; LDL, low-density 
lipoprotein; MAGIC, Meta-Analyses of Glucose and Insulin-related traits Consortium; MR, Mendelian randomization; SNP, single-
nucleotide polymorphism; TAG, triacylglycerol; and WC, waist circumference.
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are related to loci of potential importance for LDL-c signal-
ing in endothelial cells (CDH13) and for vascular biology (eg, 
TRIB1 and VEGFA), which might explain their pleiotropic 
effects regarding CHD pathogenesis.18 Last, our results are 
strengthened by the consistent strong positive associations of 
LDL-c with CHD when we use the same methods used for 
adiponectin to test this known causal effect.
Few previous studies have conducted Mendelian random-
ization analysis to investigate the effect of adiponectin on 
metabolic diseases. Two smaller studies found evidence that 
genetically raised adiponectin levels were positively associat-
ed with insulin sensitivity.32,33 However, a larger study did not 
provide evidence of a causal role of adiponectin in insulin re-
sistance or type 2 diabetes mellitus34 but found that genetical-
ly raised insulin levels are associated with lower adiponectin 
levels, suggesting that the association was possibly because 
higher insulin levels caused lower adiponectin, rather than the 
other way round.
We have undertaken the first large Mendelian random-
ization study of the causal effect of adiponectin on car-
diovascular disease risk using GWAS consortia data from 
CARDIoGRAM (22 233 CHD cases and 64 762 controls) 
and CARDIoGRAMplusC4D Metabochip (63 746 cases and 
130 681 controls) with detailed phenotyping of coronary ar-
tery disease, myocardial infarction, or both. We applied a 
rigorous analyses plan to assess the validity and consistency 
of our findings. This included (1) adopting a systematic pre-
specified approach to selecting SNPs for our instrumental 
variables; (2) exploring different scenarios from the plausi-
bly valid (but less well powered) conservative MR approach 
Figure 2. Forest plots of mean difference in log adiponectin levels and odds ratio of coronary heart disease per allele of single-
nucleotide polymorphism (SNP) according to the conservative (A) and liberal (B) approaches. A, Conservative approach including 4 
SNPs within ADIPOQ gene associated with adiponectin at genome-wide significant levels (P<5×10−8; C4). B, Liberal approach including 
17 SNPs across the genome associated with adiponectin at genome-wide significant levels (P<5×10−8; L17). CHD indicates coronary 
heart disease; Chr, chromosome; and OR, odds ratio. Results for log adiponectin included 29 347 individuals from ADIPOGen consortium 
and for CHD risk included 86 995 individuals (22 233 CHD cases) from CARDIoGRAM and 194 427 individuals (63 746 CHD cases) from 
CARDIoGRAMplusC4D Metabochip consortium.
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(restricted to SNPs within adiponectin locus) to the well-
powered (but vulnerable to horizontal pleiotropy) liberal MR 
approach (using SNPs across the genome); (3) extensively 
investigating the presence of bias because of horizontal plei-
otropy by using data from other CHD-related phenotypes (eg, 
glycemic and lipid and anthropometric traits) and methods to 
account for it (adjusted IVW method and MR-Egger method); 
(4) testing our hypotheses in 2 data sets (CARDIoGRAM and 
CARDIoGRAMplusC4D Metabochip); (5) using a very large 
sample size that provides us with 100% power to detect an 
odds ratio of 0.80 and 81% to detect and odds ratio of 0.90 
with a 0.05% type 1 error rate (Online Table III); (6) checking 
Table 2. Standardized Mean Difference (and P values) of Cardiovascular Risk Factors Per Allele of SNPs Used in Mendelian 
Randomization Analyses
Hb
A1c
Insulin HDL-c LDL-c TAG WC BMI
β P β P β P β P β P β P β P
rs1415293 0.004 0.513 −0.016 1×10−4 0.015 0.009 −0.012 0.063 −0.014 0.019 −0.006 0.200 0.004 0.283
rs1108842 −0.003 0.586 −0.009 0.027 0.008 0.077 0.010 0.024 −0.009 0.037 −0.020 2×10−8 0.011 0.001
rs6810075* −0.011 0.123 −0.005 0.214 −0.003 0.813 0.005 0.562 −0.004 0.350 0.003 0.530 −0.001 0.884
rs16861209* −0.002 0.888 −0.009 0.321 0.000 0.813 0.009 0.245 −0.001 0.610 −0.004 0.570 0.000 0.995
rs17366568* 0.000 0.984 −0.005 0.478 0.009 0.292 0.012 0.343 −0.004 0.587 −0.007 0.400 0.000 1.000
rs3774261* 0.001 0.932 −0.001 0.781 −0.006 0.108 −0.001 0.863 0.001 0.707 0.000 0.910 −0.005 0.100
rs998584 −0.014 0.045 −0.002 0.657 0.026 2×10−11 −0.001 0.936 −0.029 3×10−15 −0.029 6×10−15 0.017 9×10−7
rs2980880 0.014 0.030 0.000 0.967 0.043 1×10−26 −0.040 6×10−22 −0.067 2×10−82 0.001 0.790 0.007 0.026
rs7955516 −0.013 0.051 0.001 0.910 0.019 0.001 −0.003 0.650 −0.007 0.096 0.006 0.210 0.007 0.069
rs601339 0.005 0.528 −0.011 0.036 0.030 3×10−6 0.007 0.284 −0.016 0.013 −0.017 0.003 0.004 0.414
rs6488898 0.027 0.050 −0.004 0.642 0.026 0.007 0.016 0.198 −0.023 0.048 −0.007 0.430 0.021 0.005
rs7978610 0.000 0.959 −0.003 0.432 0.032 2×10−9 −0.020 0.001 −0.029 2×10−8 −0.021 3×10−6 0.013 0.002
rs2925979 −0.001 0.853 −0.005 0.236 0.035 1×10−19 0.003 0.630 −0.021 2×10−7 −0.011 0.003 0.001 0.721
rs7200895 0.000 0.966 0.005 0.347 0.006 0.278 −0.002 0.985 0.005 0.720 −0.001 0.850 −0.002 0.697
rs8047711 −0.020 0.329 −0.005 0.649 0.010 0.887 −0.011 0.482 −0.001 0.678 −0.006 0.700 0.000 0.982
rs12929479 0.002 0.764 −0.006 0.141 −0.008 0.530 −0.010 0.088 −0.004 0.380 −0.011 0.013 −0.016 1×10−4
rs731839 −0.007 0.288 −0.011 0.009 0.022 3×10−9 0.002 0.517 −0.022 3×10−9 0.007 0.059 0.007 0.038
SNPs within ADIPOQ gene (±50 kb) are identified by an asterisk (*). After Bonferroni correction, only P values lower than 4.2×10−4 (0.05÷17 SNPs÷7 phenotypes) 
were considered statistically significant. BMI indicates body mass index; Hb
A1c
, glycohemoglobin; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density 
lipoprotein cholesterol; TAG, triacylglycerols; and WC, waist circumference.
Figure 3. Standardized mean difference (and 95% confidence interval [CI]) in cardiovascular risk biomarkers per 1 U increase 
in genetically instrumented log adiponectin levels. A, Conservative approach including 4 SNPs within ADIPOQ gene associated with 
adiponectin at genome-wide significant levels (P<5×10−8; C4). B, Liberal approach including 17 SNPs across the genome associated with 
adiponectin at genome-wide significant levels (P<5×10−8; L17). BMI indicates body mass index; HbA1c, glycohemoglobin; HDL-c, high-
density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; SNP, single-nucleotide polymorphism; TAG, triacylglicerols; and 
WC, waist circumference.
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the consistency of our findings by performing influence meta-
analysis and a positive control analysis; and (7) using 2-sam-
ple Mendelian randomization to avoid statistical overfitting in 
comparison to Mendelian randomization where all analyses 
are conducted in the same participants35 (in a 1-sample setting, 
results could be biased in the presence of weak instruments 
because of genetic variants correlating with confounders by 
chance).
Some limitations of this study should be considered. First, 
we were not able to test for effect modification by sex, age, 
or previous disease because of the use of summary data only. 
In observational studies, the association between adiponectin 
levels and CHD outcomes is modified by factors such as the 
type of event (incident versus prevalent)10 and age of the par-
ticipant.36 Surprisingly, we did find a positive association be-
tween circulating adiponectin and CHD risk in the MR-Egger 
analysis with CARDIoGRAMplusC4D Metabochip data set, 
which is likely to be reflecting a false-positive finding because 
it was generally inconsistent with results from the conserva-
tive approach. We aimed to estimate the causal effect of total 
adiponectin concentrations, but high-molecular-weight adipo-
nectin is thought to be the biologically active fraction, and we 
are not able to specifically assess its effect. Although we have 
explored possible violation of the assumptions of Mendelian 
randomization (Online Table II), we cannot rule out bias be-
cause of possible compensatory mechanisms, known as ca-
nalization (eg, counter-regulation of adiponectin receptors 
expression because of variations in blood adiponectin concen-
tration). That said, we are not aware of any evidence that this 
might be the case.
The 2-sample Mendelian randomization assumes 
that both samples come from comparable populations. 
For our discovery analyses, this was the case, whereas in 
CARDIoGRAMplusC4D Metabochip, although the major-
ity of the participants were of European ancestry (the same 
as in ADIPOGen), 9% were from other ethnic backgrounds. 
However, we think it is unlikely that this will have resulted in a 
major source of bias. First, double genomic control for ethnic-
ity was undertaken in CARDIoGRAMplusC4D Metabochip to 
control for confounding by population stratification. Second, 
we found little evidence of heterogeneity in the association 
of SNPs with CHD in the 2 consortia, which suggests that 
(strong) effect modification by genomic ancestry is unlikely. 
Last, in a positive control study, we showed that 2-sample 
Mendelian randomization produced similar evidence for the 
expected positive causal effect of LDL-c on CHD.
Adiponectin concentration in the blood ranges from 1 
to 30 ng/mL in healthy adults, which is ≈103- to 106-folds 
higher than the concentration of many hormones and cyto-
kines.37 Blood adiponectin concentration is a modifiable risk 
factor that can be efficiently targeted by lifestyle modifica-
tions, mainly weight loss and dietary changes.38 Our results 
reinforce that Mendelian randomization studies can be helpful 
in prioritizing potential drug or lifestyle targets, which could 
substantially reduce the high costs associated with the devel-
opment and evaluation of large numbers of compounds or life-
style changes that fail along the development process.
Overall, our findings are not supportive of a protective role 
of adiponectin in CHD and indicate that the association of ge-
netically increased adiponectin levels and lower risk of CHD is 
mainly driven by horizontal pleiotropy.
Acknowledgments
We thank Frank Dudbridge (London School of Hygiene and 
Tropical Medicine, UK) and Alexandre Pereira (Heart Institute, 
University of Sao Paulo, Brazil) for the helpful comments on the 
study design and analysis. Data on adiponectin have been contrib-
uted by ADIPOGen Consortium and have been downloaded from 
https://www.mcgill.ca/genepi/adipogen-consortium. Data on coro-
nary artery disease/myocardial infarction have been contributed by 
CARDIoGRAMplusC4D investigators and have been downloaded 
from www.CARDIOGRAMPLUSC4D.ORG. Data on glycemic 
traits have been contributed by MAGIC investigators and have been 
downloaded from www.magicinvestigators.org. Data on lipid traits 
have been contributed by Global Lipids Genetics Consortium and 
have been downloaded from http://csg.sph.umich.edu/abecasis/pub-
lic/lipids2013/. Data on anthropometric traits have been contributed 
by Genetic Investigation of ANthropometric Traits (GIANT) consor-
tium and have been downloaded from http://www.broadinstitute.org/
collaboration/giant/index.php/GIANT_consortium_data_files. All 
Figure 4. Mendelian randomization estimates 
of odds ratio (and 95% confidence interval 
[CI]) of coronary heart disease risk per 1 
U increase in genetically instrumented log 
adiponectin levels. CHD indicates coronary heart 
disease; IVW, inverse-variance weighted; MR-
Egger, Mendelian randomization-Egger method; 
OR, odds ratio; and SNP, single-nucleotide 
polymorphism.
CARDIoGRAM
Conservative
Liberal
Liberal
Liberal
CARDIoGRAMplusC4D
Conservative
Liberal
Liberal
Liberal
Approach
4
17
17
17
4
17
17
17
SNPs
IVW
IVW
IVW
MR−Egger
IVW
IVW
IVW
MR−Egger
Method
No
No
Yes
Yes
No
No
Yes
Yes
Adjusted
0.83 (0.68, 1.01)
0.76 (0.65, 0.89)
0.88 (0.75, 1.03)
1.25 (0.96, 1.63)
0.97 (0.84, 1.12)
0.83 (0.74, 0.93)
1.00 (0.90, 1.12)
1.30 (1.06, 1.58)
OR CHD (95% CI)
1.00.6 0.8 1.2 1.8
 by guest on Septem
ber 8, 2016
http://circres.ahajournals.org/
D
ow
nloaded from
 
498  Circulation Research  July 22, 2016
the data used are publicly available (Online Table I). Those people 
acknowledged here and who have made their genome-wide data 
available to scientist may not necessarily agree with comments made 
in this article, and the authors take full responsibility for the contents 
of this article.
Sources of Funding
M.C. Borges receives financial support from Conselho Nacional de 
Desenvolvimento Científico e Tecnológico (CNPq) (fellowship num-
bers: 144749/2014 -9, 380946/2016-5, and 201498/2014 -6 [Science 
Without Borders Program]) and Coordenação de Aperfeiçoamento 
de Pessoal de Nível Superior. D.A. Lawlor works in a Unit that 
receives funding from the UK Medical Research Council (MC_
UU_12013/5) and is a UK National Institute of Health Research 
Senior Investigator (NF-SI-0611-10196). C. de Oliveira works in the 
English Longitudinal Study of Ageing that receives funding from the 
National Institute on Aging in the United States (grant number 5 R01 
AG017644-16) and a consortium of UK government departments co-
ordinated by the Office for National Statistics. J. White is a University 
College London core-funded researcher.
Author Contributions: M.C. Borges, D.A. Lawlor, C. de Oliveira, 
B.L. Horta, and A.J.D. Barros designed the study. M.C. Borges, D.A. 
Lawlor, J. White, and A.J.D. Barros conceived the analysis plan. M.C. 
Borges and C. de Oliveira assisted in data acquisition (from public 
data basis). M.C. Borges performed analyses. M.C. Borges wrote first 
draft of article. D.A. Lawlor, C. de Oliveira, J. White, B.L. Horta, and 
A.J.D. Barros were responsible for critical comments and contribu-
tions to final writing of article.
Disclosures
None.
References
 1. Yamauchi T, Nio Y, Maki T, et al. Targeted disruption of AdipoR1 and 
AdipoR2 causes abrogation of adiponectin binding and metabolic actions. 
Nat Med. 2007;13:332–339. doi: 10.1038/nm1557.
 2. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, 
adiponectin, suppresses lipid accumulation and class A scavenger recep-
tor expression in human monocyte-derived macrophages. Circulation. 
2001;103:1057–1063.
 3. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clini-
cal implications. Diabetologia. 2012;55:2319–2326. doi: 10.1007/
s00125-012-2598-x.
 4. Wildman RP, Mancuso P, Wang C, Kim M, Scherer PE, Sowers MR. 
Adipocytokine and ghrelin levels in relation to cardiovascular disease risk 
factors in women at midlife: longitudinal associations. Int J Obes (Lond). 
2008;32:740–748. doi: 10.1038/sj.ijo.0803782.
 5. Yamamoto Y, Hirose H, Saito I, Nishikai K, Saruta T. Adiponectin, 
an adipocyte-derived protein, predicts future insulin resistance: two-
year follow-up study in Japanese population. J Clin Endocrinol Metab. 
2004;89:87–90. doi: 10.1210/jc.2003-031163.
 6. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 
2 diabetes: a systematic review and meta-analysis. JAMA. 2009;302:179–
188. doi: 10.1001/jama.2009.976.
 7. Zhang H, Mo X, Hao Y, Huang J, Lu X, Cao J, Gu D. Adiponectin levels 
and risk of coronary heart disease: a meta-analysis of prospective studies. 
Am J Med Sci. 2013;345:455–461. doi: 10.1097/MAJ.0b013e318262dbef.
 8. Zhang BC, Liu WJ, Che WL, Xu YW. Serum total adiponectin level and 
risk of cardiovascular disease in Han Chinese populations: a meta-analysis 
of 17 case-control studies. Clin Endocrinol (Oxf). 2012;77:370–378. doi: 
10.1111/j.1365-2265.2011.04260.x.
 9. Hao G, Li W, Guo R, Yang JG, Wang Y, Tian Y, Liu MY, Peng YG, Wang ZW. 
Serum total adiponectin level and the risk of cardiovascular disease in gen-
eral population: a meta-analysis of 17 prospective studies. Atherosclerosis. 
2013;228:29–35. doi: 10.1016/j.atherosclerosis.2013.02.018.
 10. Sook Lee E, Park SS, Kim E, Sook Yoon Y, Ahn HY, Park CY, Ho Yun 
Y, Woo Oh S. Association between adiponectin levels and coronary 
heart disease and mortality: a systematic review and meta-analysis. Int J 
Epidemiol. 2013;42:1029–1039. doi: 10.1093/ije/dyt087.
 11. Kanhai DA, Kranendonk ME, Uiterwaal CS, van der Graaf Y, Kappelle LJ, 
Visseren FL. Adiponectin and incident coronary heart disease and stroke. 
A systematic review and meta-analysis of prospective studies. Obes Rev. 
2013;14:555–567. doi: 10.1111/obr.12027.
 12. Smith GD, Ebrahim S. ‘Mendelian randomization’: can genetic epidemi-
ology contribute to understanding environmental determinants of disease? 
Int J Epidemiol. 2003;32:1–22.
 13. Collaboration CRPCHDG, Wensley F, Gao P et al. Association between 
c reactive protein and coronary heart disease: Mendelian randomisation 
analysis based on individual participant data. BMJ. 2011;342:d548
 14. Sarwar N, Butterworth AS, Freitag DF, et al.; IL6R Genetics Consortium 
Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways 
in coronary heart disease: a collaborative meta-analysis of 82 studies. 
Lancet. 2012;379:1205–1213. doi: 10.1016/S0140-6736(11)61931-4.
 15. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al.; DIAGRAM 
Consortium; MAGIC Consortium; InterAct Consortium. HMG-coenzyme 
A reductase inhibition, type 2 diabetes, and bodyweight: evidence from 
genetic analysis and randomised trials. Lancet. 2015;385:351–361. doi: 
10.1016/S0140-6736(14)61183-1.
 16. Dastani Z, Johnson T, Kronenberg F, Nelson CP, Assimes TL, März W, Richards 
JB; CARDIoGRAM Consortium; ADIPOGen Consortium. The shared allelic 
architecture of adiponectin levels and coronary artery disease. Atherosclerosis. 
2013;229:145–148. doi: 10.1016/j.atherosclerosis.2013.03.034.
 17. Persson J, Strawbridge RJ, McLeod O, et al.; IMPROVE Study Group. 
Sex-Specific Effects of Adiponectin on Carotid Intima-Media Thickness 
and Incident Cardiovascular Disease. J Am Heart Assoc. 2015;4:e001853. 
doi: 10.1161/JAHA.115.001853.
 18. Dastani Z, Hivert MF, Timpson N, et al.; DIAGRAM+ Consortium; 
MAGIC Consortium; GLGC Investigators; MuTHER Consortium; 
DIAGRAM Consortium; GIANT Consortium; Global B Pgen Consortium; 
Procardis Consortium; MAGIC investigators; GLGC Consortium. Novel 
loci for adiponectin levels and their influence on type 2 diabetes and 
metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS 
Genet. 2012;8:e1002607. doi: 10.1371/journal.pgen.1002607.
 19. Schunkert H, König IR, Kathiresan S, et al.; Cardiogenics; CARDIoGRAM 
Consortium. Large-scale association analysis identifies 13 new suscepti-
bility loci for coronary artery disease. Nat Genet. 2011;43:333–338. doi: 
10.1038/ng.784.
 20. Deloukas P, Kanoni S, Willenborg C, et al. Large-scale association 
analysis identifies new risk loci for coronary artery disease. Nat Genet. 
2013;45:25–33
 21. Soranzo N, Sanna S, Wheeler E, et al.; WTCCC. Common variants at 10 
genomic loci influence hemoglobin A1C levels via glycemic and nonglyce-
mic pathways. Diabetes. 2010;59:3229–3239. doi: 10.2337/db10-0502.
 22. Dupuis J, Langenberg C, Prokopenko I, et al.; DIAGRAM Consortium; 
GIANT Consortium; Global BPgen Consortium; Anders Hamsten on be-
half of Procardis Consortium; MAGIC investigators. New genetic loci im-
plicated in fasting glucose homeostasis and their impact on type 2 diabetes 
risk. Nat Genet. 2010;42:105–116. doi: 10.1038/ng.520.
 23. Willer CJ, Schmidt EM, Sengupta S, et al.; Global Lipids Genetics 
Consortium. Discovery and refinement of loci associated with lipid levels. 
Nat Genet. 2013;45:1274–1283. doi: 10.1038/ng.2797.
 24. Locke AE, Kahali B, Berndt SI, et al.; LifeLines Cohort Study; ADIPOGen 
Consortium; AGEN-BMI Working Group; CARDIOGRAMplusC4D 
Consortium; CKDGen Consortium; GLGC; ICBP; MAGIC Investigators; 
MuTHER Consortium; MIGen Consortium; PAGE Consortium; ReproGen 
Consortium; GENIE Consortium; International Endogene Consortium. 
Genetic studies of body mass index yield new insights for obesity biology. 
Nature. 2015;518:197–206. doi: 10.1038/nature14177.
 25. Shungin D, Winkler TW, Croteau-Chonka DC, et al.; ADIPOGen 
Consortium; CARDIOGRAMplusC4D Consortium; CKDGen 
Consortium; GEFOS Consortium; GENIE Consortium; GLGC; ICBP; 
International Endogene Consortium; LifeLines Cohort Study; MAGIC 
Investigators; MuTHER Consortium; PAGE Consortium; ReproGen 
Consortium. New genetic loci link adipose and insulin biology to body fat 
distribution. Nature. 2015;518:187–196. doi: 10.1038/nature14132.
 26. Burgess S, Butterworth A, Thompson SG. Mendelian randomization 
analysis with multiple genetic variants using summarized data. Genet 
Epidemiol. 2013;37:658–665. doi: 10.1002/gepi.21758.
 27. Burgess S, Dudbridge F, Thompson SG. Re: “Multivariable Mendelian 
randomization: the use of pleiotropic genetic variants to estimate causal 
effects”. Am J Epidemiol. 2015;181:290–291. doi: 10.1093/aje/kwv017.
 28. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity anal-
yses for robust causal inference from mendelian randomization analyses 
with multiple genetic variants. Epidemiology (in press). 2016
 by guest on Septem
ber 8, 2016
http://circres.ahajournals.org/
D
ow
nloaded from
 
Borges et al  Adiponectin and Coronary Heart Disease Risk  499
 29. Greco M FD, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy 
in Mendelian randomisation studies with summary data and a continuous 
outcome. Stat Med. 2015;34:2926–2940. doi: 10.1002/sim.6522.
 30. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis 
detected by a simple, graphical test. BMJ. 1997;315:629–634.
 31. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with 
invalid instruments: effect estimation and bias detection through Egger 
regression. Int J Epidemiol. 2015;44:512–525. doi: 10.1093/ije/dyv080.
 32. Gao H, Fall T, van Dam RM, Flyvbjerg A, Zethelius B, Ingelsson E, Hägg 
S. Evidence of a causal relationship between adiponectin levels and insulin 
sensitivity: a Mendelian randomization study. Diabetes. 2013;62:1338–
1344. doi: 10.2337/db12-0935.
 33. Mente A, Meyre D, Lanktree MB, Heydarpour M, Davis AD, Miller 
R, Gerstein H, Hegele RA, Yusuf S, Anand SS; SHARE Investigators; 
SHARE-AP Investigators. Causal relationship between adiponectin and 
metabolic traits: a Mendelian randomization study in a multiethnic popu-
lation. PLoS One. 2013;8:e66808. doi: 10.1371/journal.pone.0066808.
 34. Yaghootkar H, Lamina C, Scott RA, et al.; GENESIS Consortium; RISC 
Consortium. Mendelian randomization studies do not support a causal role 
for reduced circulating adiponectin levels in insulin resistance and type 2 
diabetes. Diabetes. 2013;62:3589–3598. doi: 10.2337/db13-0128.
 35. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG; 
EPIC- InterAct Consortium. Using published data in Mendelian 
randomization: a blueprint for efficient identification of causal risk 
factors. Eur J Epidemiol. 2015;30:543–552. doi: 10.1007/s10654- 
015-0011-z.
 36. Wannamethee SG, Welsh P, Whincup PH, Sawar N, Thomas MC, 
Gudnarsson V, Sattar N. High adiponectin and increased risk of cardio-
vascular disease and mortality in asymptomatic older men: does NT-
proBNP help to explain this association? Eur J Cardiovasc Prev Rehabil. 
2011;18:65–71. doi: 10.1097/HJR.0b013e32833b09d9.
 37. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-
specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 
1999;257:79–83.
 38. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella 
R, Giugliano D. Effect of weight loss and lifestyle changes on vascu-
lar inflammatory markers in obese women: a randomized trial. JAMA. 
2003;289:1799–1804. doi: 10.1001/jama.289.14.1799.
What Is Known?
•	 Adiponectin is a protein produced mainly by mature adipose cells.
•	 Higher circulating adiponectin levels are associated with lower car-
diometabolic risk.
•	 Some genetic variants are associated with both circulating adiponectin 
and coronary heart disease risk.
What New Information Does This Article Contribute?
•	 Our findings do not support a causal effect of circulating adiponectin 
levels on the risk of coronary heart disease (CHD).
•	 Genetic variants that are associated with both circulating adiponectin 
levels and CHD have pleiotropic effects and do not reflect a direct role 
of circulating adiponectin in CHD development.
Higher circulating adiponectin levels are associated with better 
cardiometabolic profile; however, it is unknown whether this as-
sociation is causal or merely correlative because of confounding 
factors. We used genetic variants associated with circulating adi-
ponectin levels to test whether adiponectin is causally involved 
in CHD development, a technique known as Mendelian random-
ization. Overall, our findings do not support a causal effect of 
adiponectin on CHD risk, indicating that primary perturbation of 
circulating adiponectin is unlikely to be a major cause of CHD. 
Interventions targeting total circulating adiponectin might not be 
appropriate therapeutic strategies for primary CHD prevention.
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SUPPLEMENTAL MATERIAL 
 
  
Supplemental Methods 
Inverse variance weighted (IVW) method 
 
For unadjusted and adjusted Mendelian randomization analyses, the 
inverse variance weighted (IVW) method was used to derive the beta coefficient 
(log odds ratio of CHD per 1 natural log greater adiponectin level) and its standard 
error by using the following formulas: 
 
?̂?IVW = 
∑ 𝑋𝑘𝑌𝑘
𝐾
𝑘=1 𝜎𝑦𝑘
−2
∑ 𝑋𝑘
2𝜎𝑦𝑘
−2 𝐾𝑘=1
                        𝑆𝐸?̂?IVW =  √
1
∑ 𝑋𝑘
2𝜎𝑦𝑘
−2 𝐾𝑘=1
 
 
Where Xk is the mean change in log adiponectin level per additional effect 
allele of SNP k and Yk is the mean change in log odds of CHD per additional effect 
allele of SNP k with standard error σYk.   
The IVW method was also used to estimate the effect of adiponectin on 
cardiovascular risk factors (HbA1c, fasting insulin levels, HDL-c, LDL-c, TAG, BMI, 
and WC) (Xk: mean change in log adiponectin level per additional effect allele of 
SNP k, Yk: mean change in the risk factor per additional effect allele of SNP k; σYk: 
standard error of Yk). 
To estimate the association of genetically raised adiponectin and CHD in 
the model adjusted for cardiovascular risk factors, we used betas for SNP-CHD 
association as the dependent variable, betas for SNP-adiponectin and SNP-
cardiovascular risk factors as independent variables and inverse variance weights 
(with no intercept). This method is equivalent to IVW method when there is only 
one independent variable 1. 
 MR-Egger regression method 
The Egger regression has been used for almost two decades to detect 
small study bias (which may be due to publication bias) in meta-analyses of 
randomized clinical trials 2. In this method, the ratio of the effect estimate by its 
standard error is regressed against the estimate’s precision (the inverse of the 
standard error). Bowden et al. 3 recently proposed an adaptation of the Egger 
regression to test for bias from horizontal pleiotropy in Mendelian randomization 
studies. 
While the IVW estimate is equivalent to the slope of the best fitting line 
through the observations that pass through the origin, the MR-Egger estimate 
would be the best fitting line through the observations in a model that allows the 
intercept to vary. In this method, the intercept will reflect the average pleiotropic 
effect across genetic variants (e.g. log odds CHD per allele when difference in 
adiponectin per allele is zero) and the slope coefficient will provide an estimate of 
the causal effect provided that the InSIDE (Instrument Strength Independent of 
Direct Effect) assumption holds, which requires that there is no correlation 
between SNP-exposure association and direct effects of SNP on outcome. 
Bootstrapping (10,000 iterations) was used to derive corrected 95% 
confidence intervals for MR-Egger intercept and slope using the percentile method 
3. 
 
Positive control analysis 
The positive control consisted of a Mendelian randomization analysis in 
which LDL-c was the biomarker of interest and CHD risk was the outcome. 58 
SNPs were reported as strongly associated with LDL-c in GLGC consortium 4. Of 
there, 38 could be found in both Cardiogram and CARDIoGRAMplusC4D 
Metabochip dataset and, thus, were used as the instrumental variable for LDL-c. 
The crude IVW method was used to estimate the association of LDL-c with CHD 
risk. Since many SNPs were also associated with other lipid traits (ex: HDL-c, TAG 
and total cholesterol), the MR-Egger method was also used. 
 
 
 
  
Online Tables
Online Table I. Characteristics of the data sources 
Consortium Use Studies Study population Imputation QC criteria† Model Adjustments Data download 
ADIPOGen 
SNP-log 
adiponectin 
16 cohort studies 
with GWAS data 
29,347 individuals 
of European 
ancestry 
IMPUTE, MACH, 
BIMBAM or Beagle 
(reference: Phase II 
CEU HapMap 
population) 
Call rate > 0·95; MAF > 0·01; p HWE > 10
-6; and quality 
measures for imputed SNPs (r2 ≥ 0·3, or proper info ≥ 0·4) 
additive 
Age, sex, BMI, principal 
components of genomic ancestry, 
study site (where appropriate), 
family structure (one family-based 
study) and genomic control 
inflation factor (λ) 
https://www.mcgill.
ca/genepi/adipogen-
consortium 
CARDIoGRAM§ 
SNP-log odds 
CHD 
14 case-control 
or cohort studies 
with GWAS data 
22,233 CHD cases 
and 64,762 controls 
of European 
ancestry 
IMPUTE, MACH or 
BIMBAM (reference: 
CEU HapMap 
population) 
Sample cal rate > 0·97-0·98; SNP call rate > 0·95-0·99; MAF 
> 0·01; p HWE ≤ 10
-3- 10-6; ethnic outliers. Quality measures 
for imputed SNPs: NR* 
additive 
Age, sex and genomic control 
inflation factor (λ) 
http://www.cardiogr
amplusc4d.org/down
loads/ 
CARDIoGRAMplus
C4D Metabochip§ 
SNP-log odds 
CHD 
48 case-control 
or cohort studies 
with GWAS data 
 
63,746 CHD cases 
and 130,681 
controls of 
European (~91%) 
and Asianancestry 
NA, Minimac or 
IMPUTE (reference: 
HapMap 2/3 or 1000 
Genomes Project phase 
1) 
Sample call rate > 0·98; MAF > 0·01; p HWE > 10
-4; and other 
study-specific criteria 
 
additive 
Age, sex and genomic control 
inflation factor (λ) 
http://www.cardiogr
amplusc4d.org/down
loads/ 
MAGIC 
SNP-HbA1c (%) 
23 cohort studies 
with GWAS data 
35,920 individuals 
of European 
ancestry 
IMPUTE or MACH 
(reference: CEU 
HapMap population) 
Sample call rate > 0·95-0·97; SNP call rate > 0·90-0·95; 
MAF > 0·01; p HWE > 10
-4-10-6; sex mismatch between 
genotyped and reported sex; outliers as assessed by 
population structure analysis; and quality measures for 
imputed SNPs (r2 ≥ 0·3, or proper info ≥ 0·4, and MAF > 
0·01) additive 
Age, sex, other cohort-specific 
variables as applicable, and 
genomic control inflation factor (λ) 
http://www.magicin
vestigators.org/down
loads/ 
SNP-log fasting 
insulin 
20 cohort studies 
with GWAS data 
38,238 individuals 
of European 
ancestry 
IMPUTE, MACH or 
BIMBAM (reference: 
CEU HapMap 
population) 
Sample call rate > 0·94-0·99; SNP call rate > 0·90- 0·95; 
MAF > 0·01-0·05; p HWE > 10
-4-10-7; and quality measures for 
imputed SNPs (r2 ≥ 0·3, proper info ≥ 0·4 or 
observed/expected variance ratio > 0·3) 
GLGC 
SNP-HDLc 60 cohort and 
case control 
studies with 
GWAS or 
Metabochip data 
188,577 European-
ancestry 
individuals 
MACH (reference: 
CEU HapMap 
population) 
Quality control: NR* additive 
Age, sex, principal components of 
genomic ancestry (some studies), 
and genomic control inflation 
factor (λ).  Individuals taking lipid-
lowering medications were 
excluded. 
http://csg.sph.umich.
edu/abecasis/public/l
ipids2013/ 
SNP-LDLc 
SNP-TAG 
GIANT SNP- BMI 
114 studies of 
multiple designs 
with GWAS or 
Metabochip data 
up to 322,154 
individuals of 
European ancestry 
IMPUTE, MACH or 
BIMBAM (reference: 
Phase II CEU HapMap 
population) 
Sample cal rate > 0·80-0·98; SNP call rate > 0·90-0·99; MAF 
> 0·01-0·05; p HWE > 10
-3-10-7; and quality measures for 
imputed SNPs (r2 ≥ 0·3, proper info ≥ 0·4, or no filtering) 
additive 
Age, age2, and study specific 
variables (e.g. principal 
components of genomic ancestry), 
and genomic control inflation 
factor (λ) 
http://www.broadins
titute.org/collaborati
on/giant/index.php/
GIANT_consortium
_data_files 
SNP-BMI-
adjusted WC 
101 studies of 
multiple designs 
with GWAS or 
Metabochip data 
up to 210,088 
individuals of 
European ancestry 
IMPUTE, MACH or 
Beagle (reference: 
Phase II CEU HapMap 
population) 
Sample cal rate > 0·85-0·98; SNP call rate > 0·90-0·99; MAF 
> 0·00-0·01; p HWE > 10
-3-10-7; and quality measures for 
imputed SNPs (r2 ≥ 0·3, proper info ≥ 0·4, or no filtering) 
Age, age2, BMI and study specific 
variables (e.g. principal 
components of genomic ancestry), 
and genomic control inflation 
factor (λ) 
† Quality control criteria varied across studies; * NR: not reported in the main consortium publication. § CHD was defined as the presence of coronary artery disease or 
myocardial infarction. Detailed criteria for CHD definition for each study can be found in the Supplementary material of the main publications 
5-7
. QC: quality control; 
GWAS: genome-wide association study; CEU: Centre d’Etude du Polymorphisme Humain collected in Utah; CHD: coronary heart disease; MAF: minor allele frequency; 
SNP: single nucleotide polymorphism; BMI: body mass index; WC: waist circumference; NR: not reported; NA: not applicable. CARDIoGRAM: Coronary ARtery DIsease 
Genome-wide Replication And Meta-analysis; MAGIC: Meta-Analyses of Glucose and Insulin-Related Traits Consortium; GLGC: Global Lipids Genetics Consortium; 
GIANT: Genetic Investigation of ANthropometric Traits. 
Online Table I. Characteristics of the data sources (continued) 
(continued) 
 
Online Table II. Core instrumental variable assumptions and strategies to address them 
Assumption Graphical examples of 
assumption violation* 
Consequences of potential 
violation 
Validation of assumption in the current 
analysis 
 
1. IV should be 
(strongly) 
associated 
with the 
exposure 
 
 
 
 
A weak association between 
the IV and E can reduce 
precision and introduce weak 
instrument bias, which tends to 
bias the causal estimate 
towards the OLS estimate in 
one-sample MR 
- The strength of SNPs-adiponectin association 
was explored using the F-statistic (F > 20 for 
every SNP)  
 
- In two-sample MR studies with non-
overlapping datasets, any bias from weak 
instruments would be in the direction of the 
null and, thus, should not result in false 
positive findings 
 
 
 
 
 
2. IV should 
only affect 
the outcome 
through the 
exposure 
 
 
 
 
 
 
 
 
Bias in MR estimate can result 
from horizontal pleiotropy (e.g. 
genetic variant itself or a 
correlated variant is associated 
with multiple pathways 
independent of the exposure); 
the direction and magnitude of 
this bias will depend on the 
direction and magnitude of the 
association path from IV to O 
that is not via E 
Issues of horizontal pleiotropy were addressed 
by three different strategies: 
 
- The association of SNPs with known CHD 
risk factors was tested. In case of evidence of 
potential pleiotropy, this was accounted for in 
the analyses 
 
- By comparing the conservative and the liberal 
approach. In the conservative approach, 
horizontal pleiotropy is less likely given that 
variants in the ADIPOQ gene are more 
plausible valid instrumental variables for 
adiponectin levels. In the liberal approach, 
there is an increased likelihood of horizontal 
pleiotropy but also increased power, since 
more variants can be selected by this approach 
 
- Using methods that account for unknown 
directional pleiotropy (MR-Egger method) 
3. IV should be 
independent 
of exposure-
outcome 
confounders  
 
In cases of population 
stratification, there could be an 
spurious association between 
IV and phenotypes 
- We cannot test for the absence of exposure-
outcome confounders relating to the IV when 
summary-level data are used, but there is 
empirical evidence that this is unlikely8 
 
- To reduce the possibility of bias due to 
population stratification, the analyses were 
restricted to only (or predominantly) European-
ancestry individuals 
 
- All consortia adjusted for genomic control 
inflation factor 
IV: instrumental variable; E: exposure; O: outcome; U: unknown confounder; X: other phenotype: G: other 
genetic variant in LD; LD: linkage disequilibrium; CHD: coronary heart disease. A dashed arrow was used to 
indicate weak association between IV and E. 
*
Adapted from Vanderweele 
9
. 
  
Online Table III. Power simulations for the Mendelian randomization analyses 
Data source Sample 
size 
Proportion 
of cases 
Type-I 
error rate 
(α) 
Original 
OR 
Equivalent 
standardized 
OR 
R
2
x-z Power 
CARDIoGRAM 86,995 25.6% 0.05 0.70 0.80 5% 100% 
CARDIoGRAM 86,995 25.6% 0.05 0.80 0.87 5% 97% 
CARDIoGRAM 86,995 25.6% 0.05 0.90 0.94 5% 42% 
CARDIoGRAMplusC4D 
Metabochip 
194,427 32.8% 0.05 0.70 0.80 5% 100% 
CARDIoGRAMplusC4D 
Metabochip 
194,427 32.8% 0.05 0.80 0.87 5% 100% 
CARDIoGRAMplusC4D 
Metabochip 
194,427 32.8% 0.05 0.90 0.94 5% 81% 
OR: Assumed true odds ratio of CHD risk per standard deviation of the exposure variable 
Conversion of original (per log adiponectin) to equivalent standardized OR (per standard unit of log adiponectin) was made 
using an external source of individual level data (1982 Pelotas Birth Cohort) with similar adiponectin distribution (adiponectin 
levels in ADIPOGen consortium: mean = 9.8 µg/ml (SD = 5.6); adiponectin levels in 1982 Pelotas Birth Cohort: mean = 9.3 
µg/ml (SD = 5.7)). 
R
2
x-z: proportion of variance explained for the association between the genetic instrument (Z) and adiponectin levels (X). Values 
approximate findings from Dastani et al 
10
 and Yaghootkar et al 
11
. 
Calculations were performed in the power calculator for Mendelian Randomization studies, available at 
http://cnsgenomics.com/shiny/mRnd/, based on the publication by Brion et al 2013 
12
.  
 
 
  
Online Figures  
 
Online Figure I. Graphical illustration of scenarios of (A) vertical pleiotropy 
(mediation) and (B) horizontal pleiotropy (bias) by CHD risk factors in the relation 
among SNPs, adiponectin levels and CHD risk. CHD: coronary heart disease; SNP: 
single nucleotide polymorphism. 
 
Online Figure II. Meta-analysis and heterogeneity analysis of Mendelian 
randomization estimates of each SNP for the association of blood adiponectin 
levels with CHD risk. CHD: coronary heart disease; SNP: single nucleotide 
polymorphism, Chr: chromosome. 
 
Online Figure III. Pooled odds ratio (and 95%CI) of coronary heart disease risk per 
unit increase in log adiponectin levels omitting one SNP at a time (influence meta-
analysis) estimated by the IVW method and by the MR-Egger method. CHD: coronary 
heart disease; IVW: inverse-variance weighted method; MR-Egger: Mendelian 
randomization-Egger method; OR: odds ratio; SNP: single nucleotide polymorphism. 
 
Online Figure IV. Log odds ratio of coronary heart disease and mean increase in log 
adiponectin levels per adiponectin raising allele in CARDIoGRAM and 
CARDIoGRAMplusC4D Metabochip. Each data point represents betas for SNP-log 
OR CHD (Y axis) and SNP-adiponectin (X axis) association (N = 17 SNPs). CHD: 
coronary heart disease; IVW: inverse-variance weighted method; MR-Egger: Mendelian 
randomization-Egger method; OR: odds ratio; SNP: single nucleotide polymorphism 
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